Intermediate for Afatinib. Afatinib (trade name: Gilotrif) is an irreversible covalent inhibitor of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and erbB-2 (HER2) for the treatment of patients with distinct types of metastatic (EGFR mutation positive) non-small cell lung carcinoma (NSCLC). Afatinib has been approved by the U.S Food and Drug Administration on July 12, 2013.
Product Name: (S)-N-(3-Chloro-4-fluorophenyl)-7-((tetrahydrofuran-3-yl)oxy)quinazoline-4,6-diamine
CAS Number: 314771-76-1
Molecular Weight:  374.8014
Molecular Formula:  C18H16ClFN4O2
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.